Provided by Tiger Fintech (Singapore) Pte. Ltd.

Kura Oncology

6.23
+0.32505.51%
Volume:545.97K
Turnover:3.38M
Market Cap:502.70M
PE:-3.08
High:6.30
Open:5.88
Low:5.78
Close:5.90
Loading ...

Kura Oncology’s Strategic Milestones and Financial Strength Bolster Buy Rating

TIPRANKS
·
09 Apr

Kura Oncology’s Promising Developments and Strategic Expansion Justify Buy Rating

TIPRANKS
·
08 Apr

Strategic Advancements and Early NDA Submission Drive Buy Rating for Kura Oncology

TIPRANKS
·
08 Apr

Kura Oncology Submits Ziftomenib NDA to FDA for Treating Acute Myeloid Leukemia

MT Newswires Live
·
08 Apr

Kura Oncology Inc: Expects to Receive Notification From FDA on This Preliminary Evaluation in Q2 of 2025

THOMSON REUTERS
·
08 Apr

Kura Oncology and Kyowa Kirin Announce Submission of New Drug Application for Ziftomenib to FDA

THOMSON REUTERS
·
08 Apr

Kura Oncology and Kyowa Kirin Announce Submission of New Drug Application for Ziftomenib to FDA

GlobeNewswire
·
08 Apr

BRIEF-Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

Reuters
·
04 Apr

Kura Oncology reports inducement grants under Nasdaq listing rule

TIPRANKS
·
04 Apr

Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

THOMSON REUTERS
·
04 Apr

Press Release: Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Dow Jones
·
04 Apr

Kura Oncology Announces Preclinical Data for Ko-2806 Selected for Oral Presentation at the 2025 Aacr Annual Meeting

THOMSON REUTERS
·
26 Mar

Kura Oncology Announces Preclinical Data for KO-2806 Selected for Oral Presentation at the 2025 AACR Annual Meeting

GlobeNewswire
·
26 Mar

Kura Oncology reports inducement grants under Nasdaq listing rule

TIPRANKS
·
07 Mar

Kura Oncology Is Maintained at Buy by UBS

Dow Jones
·
07 Mar

UBS Adjusts Price Target on Kura Oncology to $14 From $27, Keeps Buy Rating

MT Newswires Live
·
06 Mar

Analysts Are Bullish on Top Healthcare Stocks: HCA Healthcare (HCA), Kura Oncology (KURA)

TIPRANKS
·
03 Mar

Kura Oncology’s Financial Future at Risk: Dependency on Kyowa Kirin for Ziftomenib Development Raises Concerns

TIPRANKS
·
02 Mar

Kura Oncology (NASDAQ:KURA) shareholders have endured a 64% loss from investing in the stock a year ago

Simply Wall St.
·
28 Feb

Analysts Offer Insights on Healthcare Companies: Keros Therapeutics (KROS), Kura Oncology (KURA) and Silence Therapeutics (SLN)

TIPRANKS
·
28 Feb